← Earnings Calls
SNA FY2025 Q3 Improving

Snap-On Incorporated earnings call

Oct 16, 2025 · 06:00 ET Aldo PagliariNick PinchukSarah Verbsky earningscall_biz
Buzzberg read

Tools group shows unusual sequential sales growth, signaling momentum

Snap-On reported Q3 FY2025 results with 3% organic sales growth and EPS of $5.02 ($4.71 ex-legal benefit), the highest ever for a third quarter. Management highlighted momentum across all segments, particularly RS&I (8.9% organic growth) and tools group sequential improvement, while the CNI group faced headwinds from Asia-Pacific supply chain relocations. The tone was optimistic about resilience and market share gains despite tariff and macroeconomic uncertainties. Total sales of $1.19B (+3.8% as reported, +3% organic); EPS $5.02 ($4.71 ex-legal) – record Q3.

Buzzberg read Tools group shows unusual sequential sales growth, signaling momentum Snap-On reported Q3 FY2025 results with 3% organic sales growth and EPS of $5.02 ($4.71 ex-legal benefit), the highest ever for a third quarter. Management highlighted momentum across all segments, particularly RS&I (8.9% organic growth) and tools group sequential improvement, while the CNI group faced headwinds from Asia-Pacific supply chain relocations. The tone was optimistic about resilience and market share gains despite tariff and macroeconomic uncertainties. Total sales of $1.19B (+3.8% as reported, +3% organic); EPS $5.02 ($4.71 ex-legal) – record Q3. Read full analysisCollapse analysis

Snap-On reported Q3 FY2025 results with 3% organic sales growth and EPS of $5.02 ($4.71 ex-legal benefit), the highest ever for a third quarter. Management highlighted momentum across all segments, particularly RS&I (8.9% organic growth) and tools group sequential improvement, while the CNI group faced headwinds from Asia-Pacific supply chain relocations. The tone was optimistic about resilience and market share gains despite tariff and macroeconomic uncertainties. Total sales of $1.19B (+3.8% as reported, +3% organic); EPS $5.02 ($4.71 ex-legal) – record Q3.

  • RS&I group posted 8.9% organic growth driven by double-digit gains with OEM dealerships and high-single-digit diagnostics sales.
  • Tools group saw 1% organic growth with sequential improvement; SFC orders up mid-single digits.
  • CNI group organic sales fell 0.8% as Asia-Pacific supply chain relocations offset gains in critical industries and specialty torque.
Revenue$1.2919BReported
EPS$4.71Reported
Gross margin52.23%Reported
Operating margin26.89%Reported
6 grounded callouts

What matters now

The highest-signal changes from the call.

01
Demand

Tools group shows unusual sequential sales growth, signaling momentum

02
Growth

RS&I achieves 8.9% organic growth with strong OEM dealership gains

03
Demand

Technicians remain cautious on big-ticket purchases amid uncertainty

Show 3 more callouts
04
Growth

Critical industries show order book growth despite macro uncertainty

05
Sales channel

SFC orders up mid-single digits, franchisee sentiment confident

06
Supply chain

Tariff environment managed via local manufacturing, but costs persist

Reported period

Actuals

MetricReportedChange
Revenue$1.2919BReported
EPS$4.71Reported
Gross margin52.23%Reported
Operating margin26.89%Reported
Free cash flow$0.258BReported
Capex$0.0199BReported
Forward-looking

Forward guidance

MetricPeriodRangeMidpointStatus
CapexFY2025$0.1B$0.1BGuided
AI, capex & demand read

Management read

Tone

Upbeat

Management repeatedly used language like 'encouraging momentum,' 'unmistakable momentum,' 'resilience,' and 'we leave the quarter more confident and stronger,' highlighting progress despite headwinds.

Capex

Investment and capacity

Management expects capital expenditures for the full year to approximate $100 billion (likely a typo for $100 million). The company has been investing in capacity over the last two and a half years to better match volume ups and downs, and this capacity is helping fulfill orders faster.

Methodology & coverage

Management-only analysis. All 0 validated company mentions are shown. Reported actuals and forward guidance are kept separate. Public evidence is limited to eight short attributed quotes. AI-generated analysis can be incomplete or wrong; verify important claims against the original source.